125 related articles for article (PubMed ID: 19847281)
1. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.
Khalifa KA; Alkilani AA; Ismail H; Soliman MA
J Egypt Natl Canc Inst; 2008 Mar; 20(1):47-54. PubMed ID: 19847281
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
3. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
[TBL] [Abstract][Full Text] [Related]
4. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K
Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
[TBL] [Abstract][Full Text] [Related]
6. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
Li D; Li G; Wang B
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression.
Molica S; Vitelli G; Levato D; Giannarelli D; Gandolfo GM
Cancer; 2001 Aug; 92(4):713-9. PubMed ID: 11550139
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma.
Legouffe E; Rodriguez C; Picot MC; Richard B; Klein B; Rossi JF; Commes T
Leuk Lymphoma; 1998 Oct; 31(3-4):351-7. PubMed ID: 9869199
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value.
Uskudar Teke H; Gulbas Z; Bal C
J BUON; 2014; 19(1):191-7. PubMed ID: 24659663
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.
Shah N; Cabanillas F; McIntyre B; Feng L; McLaughlin P; Rodriguez MA; Romaguera J; Younes A; Hagemeister FB; Kwak L; Fayad L
Leuk Lymphoma; 2012 Jan; 53(1):50-6. PubMed ID: 21895545
[TBL] [Abstract][Full Text] [Related]
12. Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2.
Lissoni P; Bolis S; Mandalà M; Viviani S; Pogliani E; Barni S
Int J Biol Markers; 1999; 14(3):167-71. PubMed ID: 10569139
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of suppressor of cytokines signalling-3 mRNA expression from patients with non-Hodgkin lymphoma under chemotherapy.
Attia FM; Hassan AM; El-Maraghy NN; Ibrahium GH
Cancer Biomark; 2011-2012; 11(1):41-7. PubMed ID: 22820139
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of some inflammatory markers in patients with lymphoma.
Hamed Anber N; El-Sebaie AH; Darwish NHE; Mousa SA; Shamaa SS
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30814315
[No Abstract] [Full Text] [Related]
16. Lactate dehydrogenase 5 expression in Non-Hodgkin lymphoma is associated with the induced hypoxia regulated protein and poor prognosis.
Lu R; Jiang M; Chen Z; Xu X; Hu H; Zhao X; Gao X; Guo L
PLoS One; 2013; 8(9):e74853. PubMed ID: 24086384
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD44 and CD44v6 and prognosis in children with B-cell acute lymphoblastic leukemia.
Amirghofran Z; Asiaee E; Kamazani FM
Asia Pac J Clin Oncol; 2016 Sep; 12(3):e375-82. PubMed ID: 25227983
[TBL] [Abstract][Full Text] [Related]
19. Circulating CD44 and intercellular adhesion molecule-1 levels in low grade non-hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon-alpha-2a treatment.
Beksaç M; Arat M; Akan H; Koç H; Ilhan O; Ozcan M
Cancer; 2000 Oct; 89(7):1474-81. PubMed ID: 11013360
[TBL] [Abstract][Full Text] [Related]
20. Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma.
Demir I; Akan OY; Bilgir F; Yilmaz I; Bozkaya G; Bilgir O
Ir J Med Sci; 2024 Jun; 193(3):1201-1207. PubMed ID: 38270775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
